Display options
Cite
Talaulikar D, Advani RH, Branagan AR, et al. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020;4(4):e433doi: 10.1097/HS9.0000000000000433.
Talaulikar, D., Advani, R. H., Branagan, A. R., Buske, C., Dimopoulos, M. A., D'Sa, S., Kersten, M. J., Leblond, V., Minnema, M. C., Owen, R. G., Palomba, M. L., Tedeschi, A., Trotman, J., Varettoni, M., Vos, J. M., Treon, S. P., Kastritis, E., & Castillo, J. J. (2020). Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. HemaSphere, 4(4), e433. https://doi.org/10.1097/HS9.0000000000000433
Talaulikar, Dipti, et al. "Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic." HemaSphere vol. 4,4 (2020): e433. doi: https://doi.org/10.1097/HS9.0000000000000433
Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug. PMID: 32803133; PMCID: PMC7410025.
Copy Download .nbib Format: NLM
Share it on

Hemasphere. 2020 Jul 30;4(4):e433. doi: 10.1097/HS9.0000000000000433. eCollection 2020 Aug.

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic.

HemaSphere

Dipti Talaulikar, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Maria J Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis, Jorge J Castillo

Affiliations

  1. Department of Hematology, Canberra Hospital and College of Health and Medicine, Australian National University, Canberra, Australia.
  2. Department of Medicine, Stanford University Medical Center, Stanford, California, USA.
  3. Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  4. Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
  5. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  6. Waldenström Clinic, Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK.
  7. Department of Hematology, Cancer Center Amsterdam and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), University of Amsterdam, Amsterdam, The Netherlands.
  8. Service of Clinical Hematology, Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris, France.
  9. Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
  10. Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
  11. Lymphoma Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.
  12. Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  13. Department of Haematology, Concord Hospital, Department of Medicine, University of Sydney, Sydney, Australia.
  14. Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  15. Department of Hematology and LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam UMC, location AMC, Amsterdam, The Netherlands.
  16. Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 32803133 PMCID: PMC7410025 DOI: 10.1097/HS9.0000000000000433

Abstract

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

References

  1. J Clin Rheumatol. 2019 Dec;25(8):329-334 - PubMed
  2. Haematologica. 2017 Oct;102(10):e397-e399 - PubMed
  3. Blood. 2013 Nov 7;122(19):3276-82 - PubMed
  4. Clin Cancer Res. 2016 Apr 1;22(7):1572-82 - PubMed
  5. Clin Infect Dis. 2020 Jul 28;71(15):740-747 - PubMed
  6. Lancet. 2013 Apr 6;381(9873):1203-10 - PubMed
  7. Lancet Oncol. 2020 Mar;21(3):335-337 - PubMed
  8. Haematologica. 2018 Jul;103(7):e307-e310 - PubMed
  9. Br J Haematol. 2018 Sep;182(5):712-714 - PubMed
  10. Mol Med. 2019 Jan 15;25(1):3 - PubMed
  11. Am J Hematol. 2018 Aug;93(4):511-517 - PubMed
  12. Lancet Oncol. 2020 Apr;21(4):e181 - PubMed
  13. Blood. 2020 May 21;135(21):1912-1915 - PubMed
  14. Clin Infect Dis. 2019 Jan 7;68(2):247-255 - PubMed
  15. J Clin Oncol. 2009 Aug 10;27(23):3830-5 - PubMed
  16. Blood. 2016 Sep 8;128(10):1321-8 - PubMed
  17. Bone Marrow Transplant. 2020 Jun 8;: - PubMed
  18. Blood. 2014 Jul 24;124(4):503-10 - PubMed
  19. Arthritis Rheumatol. 2019 Nov;71(11):1812-1823 - PubMed
  20. Oncotarget. 2017 Jun 13;8(24):39218-39229 - PubMed
  21. Br J Haematol. 2020 Apr;189(2):241-243 - PubMed

Publication Types

Grant support